Recent advances in deciphering viral and host determinants of dengue virus replication and pathogenesis

Journal of Virology

Volumn 80, Issue 23, 2006, Pages 11418-11431

  Clyde, Karen ^a   Kyle, Jennifer L ^a   Harris, Eva ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; DENGUE VACCINE; GAMMA INTERFERON; INTERFERON; MONOCLONAL ANTIBODY; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA; VIRUS PROTEIN; VIRUS RNA;

CYTOKINE PRODUCTION; DENDRITIC CELL; DENGUE; DENGUE VIRUS; DISEASE SEVERITY; HUMAN; IMMUNE RESPONSE; LANGERHANS CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; SHORT SURVEY; VACCINATION; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS INFECTION; VIRUS REPLICATION;

ANIMALS; DENGUE; DENGUE VIRUS; HUMANS; VIRUS REPLICATION;

DENGUE VIRUS;

EID: 33751254102     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.01257-06     Document Type: Short Survey

References (203)

1. Aaskov, J., K. Buzacott, H. M. Thu, K. Lowry, and E. C. Holmes. 2006. Long-term transmission of defective RNA viruses in humans and Aedes mosquitoes. Science 311:236-238.
2. Alvarez, D. E., A. L. D. Ezcurra, S. Fucito, and A. V. Gamarnik. 2005. Role of RNA structures present at the 3′ UTR of dengue virus on translation, RNA synthesis, and viral replication. Virology 339:200-212.
3. Alvarez, D. E., M. F. Lodeiro, S. J. Luduena, L. I. Pietrasanta, and A. V. Gamarnik. 2005. Long-range RNA-RNA interactions circularize the dengue virus genome. J. Virol. 79:6631-6643.
4. + T cells have both protective and pathogenic roles in dengue virus infection. Immunol. Lett. 95:167-174.
5. Anderson, R. 2003. Manipulation of cell surface macromolecules by flaviviruses. Adv. Virus Res. 59:229-274.
6. Anderson, R., S. Wang, C. Osiowy, and A. C. Issekutz. 1997. Activation of endothelial cells via antibody-enhanced dengue virus infection of peripheral blood monocytes. J. Virol. 71:4226-4232.
7. Arias, C. F., F. Preugschat, and J. H. Strauss. 1993. Dengue 2 virus NS2B and NS3 form a stable complex that can cleave NS3 within the helicase domain. Virology 193:888-899.
8. Atrasheuskaya, A., P. Petzelbauer, T. M. Fredeking, and G. Ignatyev. 2003. Anti-TNF antibody treatment reduces mortality in experimental dengue virus infection. FEMS Immunol. Med. Microbiol. 35:33-42.
9. Avirutnan, P., N. Punvadee, S. Noisakran, C. Komoltri, S. Thiemmeca, K. Auethavornanan, A. Jairungsri, R. Kanlaya, N. Tangthawornchaikul, C. Puttikhunt, S. N. Pattanakitsakul, P. T. Yenchitsomanus, J. Mongkolsapaya, W. Kasinrerk, N. Sittisombut, M. Husmann, M. Blettner, S. Vasanawathana, S. Bhakdi, and P. Malasit. 2006. Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement. J. Infect. Dis. 193:1078-1088.
10. Azeredo, E. L., L. M. De Oliveira-Pinto, S. M. Zagne, D. I. Cerqueira, R. M. Nogueira, and C. F. Kubelka. 2006. NK cells, displaying early activation, cytotoxicity and adhesion molecules, are associated with mild dengue disease. Clin. Exp. Immunol. 143:345-356.
11. Balmaseda, A., S. N. Hammond, L. Perez, Y. Tellez, S. I. Saborio, J. C. Mercado, R. Cuadra, J. Rocha, M. A. Perez, S. Silva, C. Rocha, and E. Harris. 2006. Serotype-specific differences in clinical manifestations of dengue. Am. J. Trop. Med. Hyg. 74:449-456.
12. Balmaseda, A., S. N. Hammond, M. A. Perez, R. Cuadra, S. Solano, J. Rocha, W. Idiaquez, and E. Harris. 2005. Short report: assessment of the World Health Organization scheme for classification of dengue severity in Nicaragua. Am. J. Trop. Med. Hyg. 73:1059-1062.
13. Bartelma, G., and R. Padmanabhan. 2002. Expression, purification, and characterization of the RNA 5′-triphosphatase activity of dengue virus type 2 nonstructural protein 3. Virology 299:122-132.
14. Bedouelle, H., L. Belkadi, P. England, J. I. Guijarro, O. Lisova, A. Urvoas, M. Delepierre, and P. Thullier. 2006. Diversity and junction residues as hotspots of binding energy in an antibody neutralizing the dengue virus. FEBS J. 273:34-46.
15. +-dependent and require a functional Walker B motif in the helicase catalytic core. Virology 328:208-218.
16. Bente, D. A., M. W. Melkus, J. V. Garcia, and R. Rico-Hesse. 2005. Dengue fever in humanized NOD/SCID mice. J. Virol. 79:13797-13799.
17. Borish, L. C., and J. W. Steinke. 2003. Cytokines and chemokines. J. Allergy Clin. Immunol. 111:8460-8475.
18. Braga, E. L., P. Moura, L. M. Pinto, S. R. Ignacio, M. J. Oliveira, M. T. Cordeiro, and C. F. Kubelka. 2001. Detection of circulant tumor necrosis factor-alpha, soluble tumor necrosis factor p75 and interferon-gamma in Brazilian patients with dengue fever and dengue hemorrhagic fever. Mem. Inst. Oswaldo Cruz 96:229-232.
19. Burke, D. S., and S. Kliks. 2006. Antibody-dependent enhancement in dengue virus infections. J. Infect. Dis. 193:601-603.
20. Burke, D. S., A. Nisalak, D. E. Johnson, and R. M. Scott. 1988. A prospective study of dengue infections in Bangkok. Am. J. Trop. Med. Hyg. 38:172-180.
21. Cardier, J. E., E. Marino, E. Romano, P. Taylor, F. Liprandi, N. Bosch, and A. L. Rothman. 2005. Proinflammatory factors present in sera from patients with acute dengue infection induce activation and apoptosis of human microvascular endothelial cells: possible role of TNF-alpha in endothelial cell damage in dengue. Cytokine 30:359-365.
22. Carr, J. M., H. Hocking, K. Bunting, P. J. Wright, A. Davidson, J. Gamble, C. J. Burrell, and P. Li. 2003. Supernatants from dengue virus type-2 infected macrophages induce permeability changes in endothelial cell monolayers. J. Med. Virol. 69:521-528.
23. Chakravarti, A., and R. Kumaria. 2006. Circulating levels of tumour necrosis factor-α & interferon-γ in patients with dengue & dengue haemorrhagic fever during an outbreak. Indian J. Med. Res. 123:25-30.
24. Charnsilpa, W., R. Takhampunya, T. P. Endy, M. P. Mammen, D. H. Libraty, and S. Ubol. 2005. Nitric oxide radical suppresses replication of wild-type dengue 2 viruses in vitro. J. Med. Virol. 77:89-95.
25. Charo, I. F., and R. M. Ransohoff. 2006. The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. 354:610-621.
26. Chen, H. C., S. Y. Lai, J. M. Sung, S. H. Lee, Y. C. Lin, W. K. Wang, Y. C. Chen, C. L. Kao, C. C. King, and B. A. Wu-Hsieh. 2004. Lymphocyte activation and hepatic cellular infiltration in immunocompetent mice infected by dengue virus. J. Med. Virol. 73:419-431.
27. Chen, L. C., H. Y. Lei, C. C. Liu, S. C. Shiesh, S. H. Chen, H. S. Liu, Y. S. Lin, S. T. Wang, H. W. Shyu, and T. M. Yeh. 2006. Correlation of serum levels of macrophage migration inhibitory factor with disease severity and clinical outcome in dengue patients. Am. J. Trop. Med. Hyg. 74:142-147.
28. Chen, R. F., J. W. Liu, W. T. Yeh, L. Wang, J. C. Chang, H. R. Yu, J. T. Cheng, and K. D. Yang. 2005. Altered T helper 1 reaction but not increase of virus load in patients with dengue hemorrhagic fever. FEMS Immunol. Med. Microbiol. 44:43-50.
29. Chen, Y., T. Maguire, R. E. Hileman, J. R. Fromm, J. D. Esko, R. J. Linhardt, and R. M. Marks. 1997. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat. Med. 3:866-871.
30. Chen, Y. C., S. Y. Wang, and C. C. King. 1999. Bacterial lipopolysaccharide inhibits dengue virus infection of primary human monocytes/macrophages by blockade of virus entry via a CD14-dependent mechanism. J. Virol. 73:2650-2657.
31. Chiu, W. W., R. M. Kinney, and T. W. Dreher. 2005. Control of translation by the 5′- and 3′-terminal regions of the dengue virus genome. J. Virol. 79:8303-8315.
32. Chua, J. J. E., R. Bhuvanakantham, V. T. K. Chow, and M. L. Ng. 2005. Recombinant non-structural 1 (NS1) protein of dengue-2 virus interacts with human STAT3 beta protein. Virus Res. 112:85-94.
33. Chua, J. J. E., M. M. L. Ng, and V. T. K. Chow. 2004. The non-structural 3 (NS3) protein of dengue virus type 2 interacts with human nuclear receptor binding protein and is associated with alterations in membrane structure. Virus Res. 102:151-163.
34. Clyde, K., and E. Harris. 2006. RNA secondary structure in the coding region of dengue virus type 2 directs translation start codon selection and is required for viral replication. J. Virol. 80:2170-2182.
35. Cologna, R., and R. Rico-Hesse. 2003. American genotype structures decrease dengue virus output from human monocytes and dendritic cells. J. Virol. 77:3929-3938.
36. Crabtree, M. B., R. M. Kinney, and B. R. Miller. 2005. Deglycosylation of the NS1 protein of dengue 2 virus, strain 16681: construction and characterization of mutant viruses. Arch. Virol. 150:771-786.
37. Crill, W. D., and G. J. J. Chang. 2004. Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J. Virol. 78:13975-13986.
38. Crotty, S., C. E. Cameron, and R. Andino. 2001. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc. Natl. Acad. Sci. USA 98:6895-6900.
39. Cummings, D. A. T., I. B. Schwartz, L. Billings, L. B. Shaw, and D. S. Burke. 2005. Dynamic effects of antibody-dependent enhancement on the fitness of viruses. Proc. Natl. Acad. Sci. USA 102:15259-15264.
40. Deen, J. L., E. Harris, B. Wills, A. Balmaseda, S. N. Hammond, C. Rocha, N. M. Dung, N. T. Hung, T. T. Hien, and J. F. Farrar. 2006. The WHO dengue classification and case definitions: time for reassessment? Lancet 368:170-173.
41. De Nova-Ocampo, M., N. Villegas-Sepulveda, and R. M. del Angel. 2002. Translation elongation factor-1α, La, and PTB interact with the 3′ untranslated region of dengue 4 virus RNA. Virology 295:337-347.
42. Diamond, M. S., D. Edgil, T. G. Roberts, B. Lu, and E. Harris. 2000. Infection of human cells by dengue virus is modulated by different cell types and viral strains. J. Virol. 74:7814-7823.
43. Diamond, M. S., T. G. Roberts, D. Edgil, B. Lu, J. Ernst, and E. Harris. 2000. Modulation of dengue virus infection in human cells by alpha, beta, and gamma interferons. J. Virol. 74:4957-4966.
44. Diamond, M. S., M. Zachariah, and E. Harris. 2002. Mycophenolic acid inhibits dengue virus infection by preventing replication of viral RNA. Virology 304:211-221.
45. Domingo, E., and J. J. Holland. 1997. RNA virus mutations and fitness for survival. Annu. Rev. Microbiol. 51:151-178.
46. Edgil, D., M. S. Diamond, K. L. Holden, S. M. Paranjape, and E. Harris. 2003. Translation efficiency determines differences in cellular infection among dengue virus type 2 strains. Virology 317:275-290.
47. Edgil, D., and E. Harris. 2006. End-to-end communication in the modulation of translation by mammalian RNA viruses. Virus Res. 119:43-51.
48. Edgil, D., C. Polacek, and E. Harris. 2006. Dengue virus utilizes a novel strategy for translation initiation when cap-dependent translation is inhibited. J. Virol. 80:2976-2986.
49. Egloff, M. P., D. Benarroch, B. Selisko, J. L. Romette, and B. Canard. 2002. An RNA cap (nucleoside-2′-O-)-methyltransferase in the flavivirus RNA polymerase NS5: crystal structure and functional characterization. EMBO J. 21:2757-2768.
50. Endy, T. P., A. Nisalak, S. Chunsuttitwat, D. W. Vaughn, S. Green, F. A. Ennis, A. L. Rothman, and D. H. Libraty. 2004. Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J. Infect. Dis. 189:990-1000.
51. Erfan, E., M. Sadikin, A. R. Prijanti, and A. Soebandrio. 2003. Detection of anti-thrombocyte autoantibody in sera of dengue hemorrhagic fever patients. J. Clin. Virol. 28:S65-S65.
52. Espina, L. M., N. J. Valero, J. M. Hernandez, and J. A. Mosquera. 2003. Increased apoptosis and expression of tumor necrosis factor-alpha caused by infection of cultured human monocytes with dengue virus. Am. J. Trop. Med. Hyg. 68:48-53.
53. Falconar, A. K. 1997. The dengue virus nonstructural-1 protein (NS1) generates antibodies to common epitopes on human blood clotting, integrin/adhesin proteins and binds to human endothelial cells: potential implications in haemorrhagic fever pathogenesis. Arch. Virol. 142:897-916.
54. Falgout, B., M. Pethel, Y. M. Zhang, and C. J. Lai. 1991. Both nonstructural proteins NS2B and NS3 are required for the proteolytic processing of dengue virus nonstructural proteins. J. Virol. 65:2467-2475.
55. Fernandez-Mestre, M. T., K. Gendzekhadze, P. Rivas-Vetencourt, and Z. Layrisse. 2004. TNF-alpha-308A allele, a possible severity risk factor of hemorrhagic manifestation in dengue fever patients. Tissue Antigens 64:469-472.
56. Fields, B. N., D. M. Knipe, P. M. Howley, and D. E. Griffin. 2001. Fields virology, 4th ed. Lippincott Williams & Wilkins, Philadelphia, Pa.
57. Forwood, J. K., A. Brooks, L. J. Briggs, C. Y. Xiao, D. A. Jans, and S. G. Vasudevan. 1999. The 37-amino-acid interdomain of dengue virus NS5 protein contains a functional NLS and inhibitory CK2 site. Biochem. Biophys. Res. Commun. 257:731-737.
58. Garcia-Montalvo, B. M., F. Medina, and R. M. del Angel. 2004. La protein binds to NS5 and NS3 and to the 5′ and 3′ ends of dengue 4 virus RNA. Virus Res. 102:141-150.
59. Germi, R., J. M. Crance, D. Garin, J. Guimet, H. Lortat-Jacob, R. W. Ruigrok, J. P. Zarski, and E. Drouet. 2002. Heparan sulfate-mediated binding of infectious dengue virus type 2 and yellow fever virus. Virology 292:162-168.
60. Gollins, S. W., and J. S. Porterfield. 1986. The uncoating and infectivity of the flavivirus West Nile on interaction with cells: effects of pH and ammonium chloride. J. Gen. Virol. 67:1941-1950.
61. Green, S., D. H. Libraty, K. Laoprasopwattana, F. A. Ennis, and A. L. Rothman. 2006. Antibody-dependent enhancement in dengue virus infections. J. Infect. Dis. 193:603-604.
62. Green, S., S. Pichyangkul, D. W. Vaughn, S. Kalayanarooj, S. Nimmannitya, A. Nisalak, I. Kurane, A. L. Rothman, and F. A. Ennis. 1999. Early CD69 expression on peripheral blood lymphocytes from children with dengue hemorrhagic fever. J. Infect. Dis. 180:1429-1435.
63. Green, S., D. W. Vaughn, S. Kalayanarooj, S. Nimmannitya, S. Suntayakorn, A. Nisalak, A. L. Rothman, and F. A. Ennis. 1999. Elevated plasma interleukin-10 levels in acute dengue correlate with disease severity. J. Med. Virol. 59:329-334.
64. Gubler, D. J. 1998. Dengue and dengue hemorrhagic fever. Clin. Microbiol. Rev. 11:480-496.
65. Guirakhoo, F., R. A. Bolin, and J. T. Roehrig. 1992. The Murray Valley encephalitis virus prM protein confers acid resistance to virus particles and alters the expression of epitopes within the R2 domain of E glycoprotein. Virology 191:921-931.
66. Guirakhoo, F., F. X. Heinz, C. W. Mandl, H. Holzmann, and C. Kunz. 1991. Fusion activity of flaviviruses: comparison of mature and immature (prM-containing) tick-borne encephalitis virions. J. Gen. Virol. 72:1323-1329.
67. Guirakhoo, F., A. R. Hunt, J. G. Lewis, and J. T. Roehrig. 1993. Selection and partial characterization of dengue 2 virus mutants that induce fusion at elevated pH. Virology 194:219-223.
68. Guirakhoo, F., Z. Zhang, G. Myers, B. W. Johnson, K. Pugachev, R. Nichols, N. Brown, I. Levenbook, K. Draper, S. Cyrek, J. Lang, C. Fournier, B. Barrere, S. Delagrave, and T. P. Monath. 2004. A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys. J. Virol. 78:9998-10008.
69. Guzman, M. G., G. Kouri, J. Bravo, L. Valdes, S. Vazquez, and S. B. Halstead. 2002. Effect of age on outcome of secondary dengue 2 infections. Int. J. Infect. Dis. 6:118-124.
70. Guzman, M. G., G. Kouri, L. Valdes, J. Bravo, S. Vazquez, and S. B. Halstead. 2002. Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks. Rev. Panam. Salud Publica 11:223-227.
71. Hahn, C. S., Y. S. Hahn, C. M. Rice, E. Lee, L. Dalgarno, E. G. Strauss, and J. H. Strauss. 1987. Conserved elements in the 3′ untranslated region of flavivirus RNAs and potential cyclization sequences. J. Mol. Biol. 198:33-41.
72. Halstead, S. B. 2006. Measuring dengue enhancing antibodies: caveats. J. Infect. Dis. 193:601.
73. Halstead, S. B. 2003. Neutralization and antibody-dependent enhancement of dengue viruses. Adv. Virus Res. 60:421-467.
74. Halstead, S. B., and J. Deen. 2002. The future of dengue vaccines. Lancet 360:1243-1245.
75. Halstead, S. B., S. Nimmannitya, and S. N. Cohen. 1970. Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. Yale J. Biol. Med. 42:311-328.
76. Halstead, S. B., T. G. Streit, J. G. Lafontant, R. Putvatana, K. Russell, W. Sun, N. Kanesa-Thasan, C. G. Hayes, and D. M. Watts. 2001. Haiti: absence of dengue hemorrhagic fever despite hyperendemic dengue virus transmission. Am. J. Trop. Med. Hyg. 65:180-183.
77. Harris, E., E. Videa, L. Perez, E. Sandoval, Y. Tellez, M. L. Perez, R. Cuadra, J. Rocha, W. Idiaquez, R. E. Alonso, M. A. Delgado, L. A. Campo, F. Acevedo, A. Gonzalez, J. J. Amador, and A. Balmaseda. 2000. Clinical, epidemiologic, and virologic features of dengue in the 1998 epidemic in Nicaragua. Am. J. Trop. Med. Hyg. 63:5-11.
78. Hase, T., P. L. Summers, and K. H. Eckels. 1989. Flavivirus entry into cultured mosquito cells and human peripheral blood monocytes. Arch. Virol. 104:129-143.
79. Heinz, F. X., and S. L. Allison. 2003. Flavivirus structure and membrane fusion. Adv. Virus Res. 59:63-97.
80. Helt, A. M., and E. Harris. 2005. S-phase-dependent enhancement of dengue virus 2 replication in mosquito cells, but not in human cells. J. Virol. 79:13218-13230.
81. Henchal, E. A., L. S. Henchal, and J. J. Schlesinger. 1988. Synergistic interactions of anti-NS1 monoclonal antibodies protect passively immunized mice from lethal challenge with dengue 2 virus. J. Gen. Virol. 69:2101-2107.
82. Hilgard, P., and R. Stockert. 2000. Heparan sulfate proteoglycans initiate dengue virus infection of hepatocytes. Hepatology 32:1069-1077.
83. Ho, L. J., L. F. Hung, C. Y. Weng, W. L. Wu, P. Chou, Y. L. Lin, D. M. Chang, T. Y. Tai, and J. H. Lai. 2005. Dengue virus type 2 antagonizes IFN-α but not IFN-γ antiviral effect via down-regulating Tyk2-STAT signaling in the human dendritic cell. J. Immunol. 174:8163-8172.
84. Hober, D., A. S. Delannoy, S. Benyoucef, D. De Groote, and P. Wattre. 1996. High levels of sTNFR p75 and TNF alpha in dengue-infected patients. Microbiol. Immunol. 40:569-573.
85. Holden, K. L., and E. Harris. 2004. Enhancement of dengue virus translation: role of the 3′ untranslated region and the terminal 3′ stem-loop domain. Virology 329:119-133.
86. Holden, K. L., D. A. Stein, T. C. Pierson, A. A. Ahmed, K. Clyde, P. L. Iversen, and E. Harris. 2006. Inhibition of dengue virus translation and RNA synthesis by a morpholino oligomer targeted to the top of the terminal 3′ stem-loop structure. Virology 344:439-452.
87. Hombach, J., A. D. Barrett, M. J, Cardosa, V. Deubel, M. Guzman, I. Kurane, J. T. Roehrig, A. Sabchareon, and M. P. Kieny. 2005. Review on flavivirus vaccine development. Proceedings of a meeting jointly organised by the World Health Organization and the Thai Ministry of Public Health, 26-27 April 2004, Bangkok, Thailand. Vaccine 23:2689-2695.
88. Huang, K. J., S. Y. Li, S. C. Chen, H. S. Liu, Y. S. Lin, T. M. Yeh, C. C. Liu, and H. Y. Lei. 2000. Manifestation of thrombocytopenia in dengue-2-virus-infected mice. J. Gen. Virol. 81:2177-2182.
89. Huang, Y. H., H. Y. Lei, H. S. Liu, Y. S. Lin, S. H. Chen, C. C. Liu, and T. M. Yeh. 2003. Tissue plasminogen activator induced by dengue virus infection of human endothelial cells. J. Med. Virol. 70:610-616.
90. Hung, S. L., P. L. Lee, H. W. Chen, L. K. Chen, C. L. Kao, and C. C. King. 1999. Analysis of the steps involved in dengue virus entry into host cells. Virology 257:156-167.
91. Jessie, K., M. Y. Fong, S. Devi, S. K. Lam, and K. T. Wong. 2004. Localization of dengue virus in naturally infected human tissues, by immunohistochemistry and in situ hybridization. J. Infect. Dis. 189:1411-1418.
92. Jindadamrongwech, S., C. Thepparit, and D. R. Smith. 2004. Identification of GRP 78 (BiP) as a liver cell expressed receptor element for dengue virus serotype 2. Arch. Virol. 149:915-927.
93. Johnson, A. J., F. Guirakhoo, and J. T. Roehrig. 1994. The envelope glycoproteins of dengue 1 and dengue 2 viruses grown in mosquito cells differ in their utilization of potential glycosylation sites. Virology 203:241-249.
94. Johnson, A. J., and J. T. Roehrig. 1999. New mouse model for dengue virus vaccine testing. J. Virol. 73:783-786.
95. Jones, M., A. Davidson, L. Hibbert, P. Gruenwald, J. Schlaak, S. Ball, G. R. Foster, and M. Jacobs. 2005. Dengue virus inhibits alpha interferon signaling by reducing STAT2 expression. J. Virol. 79:5414-5420.
96. Kapoor, M., L. Zhang, M. Ramachandra, J. Kusukawa, K. E. Ebner, and R. Padmanabhan. 1995. Association between NS3 and NS5 proteins of dengue virus type 2 in the putative RNA replicase is linked to differential phosphorylation of NS5. J. Biol. Chem. 270:19100-19106.
97. Kaufman, B. M., P. L. Summers, D. R. Dubois, W. H. Cohen, M. K. Gentry, R. L. Timchak, D. S. Burke, and K. H. Eckels. 1989. Monoclonal antibodies for dengue virus prM glycoprotein protect mice against lethal dengue infection. Am. J. Trop. Med. Hyg. 41:576-580.
98. Kaufman, B. M., P. L. Summers, D. R. Dubois, and K. H. Eckels. 1987. Monoclonal antibodies against dengue 2 virus E-glycoprotein protect mice against lethal dengue infection. Am. J. Trop. Med. Hyg. 36:427-434.
99. Keelapang, P., R. Sriburi, S. Supasa, N. Panyadee, A. Songjaeng, A. Jairungsri, C. Puttikhunt, W. Kasinrerk, P. Malasit, and N. Sittisombut. 2004. Alterations of pr-M cleavage and virus export in pr-M junction chimeric dengue viruses. J. Virol. 78:2367-2381.
100. Kimura, T., and A. Ohyama. 1988. Association between the pH-dependent conformational change of West Nile flavivirus E protein and virus-mediated membrane fusion. J. Gen. Virol. 69:1247-1254.
101. King, A. D., A. Nisalak, S. Kalayanrooj, K. S. Myint, K. Pattanapanyasat, S. Nimmannitya, and B. L. Innis. 1999. B cells are the principal circulating mononuclear cells infected by dengue virus. Southeast Asian J. Trop. Med. Public Health 30:718-728.
102. Klaythong, R., M. Sirikong, D. Vaughn, S. Green, T. Endy, D. Libraty, B. Innis, A. Rothman, F. Ennis, D. Chandanayingyong, and H. Stephens. 2003. HLA class I allele associations with secondary dengue virus infections in ethnic Thais. Genes Immun. 4:S36-S36.
103. Kliks, S. C., A. Nisalak, W. E. Brandt, L. Wahl, and D. S. Burke. 1989. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am. J. Trop. Med. Hyg. 40:444-451.
104. Koraka, P., B. Murgue, X. Deparis, E. C. Van Gorp, T. E. Setiati, A. D. Osterhaus, and J. Groen. 2004. Elevation of soluble VCAM-1 plasma levels in children with acute dengue virus infection of varying severity. J. Med. Virol. 72:445-450.
105. Kurane, I., B. L. Innis, S. Nimmannitya, A. Nisalak, A. Meager, and F. A. Ennis. 1993. High levels of interferon alpha in the sera of children with dengue virus infection. Am. J. Trop. Med. Hyg. 48:222-229.
106. Kurane, I., B. L. Innis, S. Nimmannitya, A. Nisalak, A. Meager, J. Janus, and F. A. Ennis. 1991. Activation of T lymphocytes in dengue virus infections. High levels of soluble interleukin 2 receptor, soluble CD4, soluble CD8, interleukin 2, and interferon-gamma in sera of children with dengue. J. Clin. Investig. 88:1473-1480.
107. Laoprasopwattana, K., D. H. Libraty, T. P. Endy, A. Nisalak, S. Chunsuttiwat, D. W. Vaughn, G. Reed, F. A. Ennis, A. L. Rothman, and S. Green. 2005. Dengue virus (DV) enhancing antibody activity in preillness plasma does not predict subsequent disease severity or viremia in secondary DV infection. J. Infect. Dis. 192:510-519.
108. Lee, C. J., C. L. Liao, and Y. L. Lin. 2005. Flavivirus activates phosphatidylinositol 3-kinase signaling to block caspase-dependent apoptotic cell death at the early stage of virus infection. J. Virol. 79:8388-8399.
109. Lee, E., R. C. Weir, and L. Dalgarno. 1997. Changes in the dengue virus major envelope protein on passaging and their localization on the three-dimensional structure of the protein. Virology 232:281-290.
110. Lei, H. Y., T. M. Yeh, H. S. Liu, Y. S. Lin, S. H. Chen, and C. C. Liu. 2001. Immunopathogenesis of dengue virus infection. J. Biomed. Sci. 8:377-388.
111. Leitmeyer, K. C., D. W. Vaughn, D. M. Watts, R. Salas, I. V. de Chacon, C. Ramos, and R. Rico-Hesse. 1999. Dengue virus structural differences that correlate with pathogenesis. J. Virol. 73:4738-4747.
112. Li, H., S. Clum, S. You, K. E. Ebner, and R. Padmanabhan. 1999. The serine protease and RNA-stimulated nucleoside triphosphatase and RNA helicase functional domains of dengue virus type 2 NS3 converge within a region of 20 amino acids. J. Virol. 73:3108-3116.
113. Libraty, D. H., T. P. Endy, H. S. Houng, S. Green, S. Kalayanarooj, S. Suntayakorn, W. Chansiriwongs, D. W. Vaughn, A. Nisalak, F. A. Ennis, and A. L. Rothman. 2002. Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J. Infect. Dis. 185:1213-1221.
114. Libraty, D. H., P. R. Young, D. Pickering, T. P. Endy, S. Kalayanarooj, S. Green, D. W. Vaughn, A. Nisalak, F. A. Ennis, and A. L. Rothman. 2002. High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever. J. Infect. Dis. 186:1165-1168.
115. Lim, H. Y., and M. L. Ng. 1999. A different mode of entry by dengue-2 neutralisation escape mutant virus. Arch. Virol. 144:989-995.
116. Lin, C. F., S. C. Chiu, Y. L. Hsiao, S. W. Wan, H. Y. Lei, A. L. Shiau, H. S. Liu, T. M. Yeh, S. H. Chen, C. C. Liu, and Y. S. Lin. 2005. Expression of cytokine, chemokine, and adhesion molecules during endothelial cell activation induced by antibodies against dengue virus nonstructural protein 1. J. Immunol. 174:395-403.
117. Lin, C. F., H. Y. Lei, A. L. Shiau, C. C. Liu, H. S. Liu, T. M. Yeh, S. H. Chen, and Y. S. Lin. 2003. Antibodies from dengue patient sera cross-react with endothelial cells and induce damage. J. Med. Virol. 69:82-90.
118. Lin, S. R., S. C. Hsieh, Y. Y. Yueh, T. H. Lin, D. Y. Chao, W. J. Chen, C. C. King, and W. K. Wang. 2004. Study of sequence variation of dengue type 3 virus in naturally infected mosquitoes and human hosts: implications for transmission and evolution. J. Virol. 78:12717-12721.
119. Lin, Y. L., H. Y. Lei, Y. S. Lin, T. M. Yeh, S. H. Chen, and H. S. Liu. 2002. Heparin inhibits dengue-2 virus infection of five human liver cell lines. Antivir. Res. 56:93-96.
120. Lin, Y. L., C. L. Liao, L. K. Chen, C. T. Yeh, C. I. Liu, S. H. Ma, Y. Y. Huang, Y. L. Huang, C. L. Kao, and C. C. King. 1998. Study of dengue virus infection in SCID mice engrafted with human K562 cells. J. Virol. 72:9729-9737.
121. Lin, Y. S., C. F. Lin, H. Y. Lei, H. S. Liu, T. M. Yeh, S. H. Chen, and C. C. Liu. 2004. Antibody-mediated endothelial cell damage via nitric oxide. Curr. Pharm. Des. 10:213-221.
122. Lindenbach, B. D., and C. M. Rice. 2003. Molecular biology of flaviviruses. Adv. Virus Res. 59:23-61.
123. Lozach, P. Y., L. Burleigh, I. Staropoli, E. Navarro-Sanchez, J. Harriague, J. L. Virelizier, F. A. Rey, P. Despres, F. Arenzana-Seisdedos, and A. Amara. 2005. Dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN)-mediated enhancement of dengue virus infection is independent of DC-SIGN internalization signals. J. Biol. Chem. 280:23698-23708.
124. Mairuhu, A., T. Setiati, P. Koraka, C. Hack, A. Leyte, S. Faradz, H. Ten Cate, D. Brandjes, A. Osterhaus, P. Reitsma, and E. van Gorp. 2005. Increased PAI-1 plasma levels and risk of death from dengue: no association with the 4G/5G promoter polymorphism. Thromb. J. 3:17.
125. Mairuhu, A. T., M. R. Mac Gillavry, T. E. Setiati, A. Soemantri, H. ten Cate, D. P. Brandjes, and E. C. van Gorp. 2003. Is clinical outcome of dengue-virus infections influenced by coagulation and fibrinolysis? A critical review of the evidence. Lancet Infect. Dis. 3:33-41.
126. Mairuhu, A. T., G. Peri, T. E. Setiati, C. E. Hack, P. Koraka, A. Soemantri, A. D. Osterhaus, D. P. Brandjes, J. W. van der Meer, A. Mantovani, and E. C. van Gorp. 2005. Elevated plasma levels of the long pentraxin, pentraxin 3, in severe dengue virus infections. J. Med. Virol. 76:547-552.
127. + T cells to heterologous serotypes. J. Immunol. 175:2676-2683.
128. Medin, C. L., K. A. Fitzgerald, and A. L. Rothman. 2005. Dengue virus nonstructural protein NS5 induces interleukin-8 transcription and secretion. J. Virol. 79:11053-11061.
129. Messer, W. B., D. J. Gubler, E. Harris, K. Sivananthan, and A. M. de Silva. 2003. Emergence and global spread of a dengue serotype 3, subtype III virus. Emerg. Infect. Dis. 9:800-809.
130. Modis, Y., S. Ogata, D. Clements, and S. C. Harrison. 2003. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc. Natl. Acad. Sci. USA 100:6986-6991.
131. Modis, Y., S. Ogata, D. Clements, and S. C. Harrison. 2004. Structure of the dengue virus envelope protein after membrane fusion. Nature 427:313-319.
132. Mohan, P. M., and R. Padmanabhan. 1991. Detection of stable secondary structure at the 3′ terminus of dengue virus type 2 RNA. Gene 108:185-191.
133. Mongkolsapaya, J., W. Dejnirattisai, X. N. Xu, S. Vasanawathana, N. Tangthawornchaikul, A. Chairunsri, S. Sawasdivorn, T. Duangchinda, T. Dong, S. Rowland-Jones, P. T. Yenchitsomanus, A. McMichael, P. Malasit, and G. Screaton. 2003. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat. Med. 9:921-927.
134. Mongkolsapaya, J., T. Duangchinda, W. Dejnirattisai, S. Vasanawathana, P. Avirutnan, A. Jairungsri, N. Khemnu, N. Tangthawornchaikul, P. Chotiyarnwong, K. Sae-Jang, M. Koch, Y. Jones, A. McMichael, X. Xu, P. Malasit, and G. Screaton. 2006. T cell responses in dengue hemorrhagic fever: are cross-reactive T cells suboptimal? J. Immunol. 176:3821-3829.
135. Mukhopadhyay, S., R. J. Kuhn, and M. G. Rossmann. 2005. A structural perspective of the flavivirus life cycle. Nat. Rev. Microbiol. 3:13-22.
136. Munoz-Jordan, J. L., M. Laurent-Rolle, J. Ashour, L. Martinez-Sobrido, M. Ashok, W. I. Lipkin, and A. Garcia-Sastre. 2005. Inhibition of alpha/beta interferon signaling by the NS4B protein of flaviviruses. J. Virol. 79:8004-8013.
137. Munoz-Jordan, J. L., G. G. Sanchez-Burgos, M. Laurent-Rolle, and A. Garcia-Sastre. 2003. Inhibition of interferon signaling by dengue virus. Proc. Natl. Acad. Sci. USA 100:14333-14338.
138. Murgue, B., C. Roche, E. Chungue, and X. Deparis. 2000. Prospective study of the duration and magnitude of viraemia in children hospitalised during the 1996-1997 dengue-2 outbreak in French Polynesia. J. Med. Virol. 60:432-438.
139. Navarro-Sanchez, E., R. Altmeyer, A. Amara, O. Schwartz, F. Fieschi, J. L. Virelizier, F. Arenzana-Seisdedos, and P. Despres. 2003. Dendritic-cell- specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses. EMBO Rep. 4:723-728.
140. Navarro-Sanchez, E., P. Despres, and L. Cedillo-Barron. 2005. Innate immune responses to dengue virus. Arch. Med. Res. 36:425-435.
141. Neves-Souza, P. C. F., E. L. Azeredo, S. M. O. Zagne, R. Valles-de-Souza, S. Reis, D. I. S. Cerqueira, R. M. R. Nogueira, and C. F. Kubelka. 2005. Inducible nitric oxide synthase (iNOS) expression in monocytes during acute dengue fever in patients and during in vitro infection. BMC Infect. Dis. 5:64.
142. Nguyen, T. H., H. Y. Lei, T. L. Nguyen, Y. S. Lin, K. J. Huang, B. L. Le, C. F. Lin, T. M. Yeh, Q. H. Do, T. Q. Vu, L. C. Chen, J. H. Huang, T. M. Lam, C. C. Liu, and S. B. Halstead. 2004. Dengue hemorrhagic fever in infants: a study of clinical and cytokine profiles. J. Infect. Dis. 189:221-232.
143. Nisalak, A., T. P. Endy, S. Nimmannitya, S. Kalayanarooj, U. Thisayakorn, R. M. Scott, D. S. Burke, C. H. Hoke, B. L. Innis, and D. W. Vaughn. 2003. Serotype-specific dengue virus circulation and dengue disease in Bangkok, Thailand from 1973 to 1999. Am. J. Trop. Med. Hyg. 68:191-202.
144. Nomaguchi, M., M. Ackermann, C. Yon, S. You, and R. Padmanabhan. 2003. De novo synthesis of negative-strand RNA by dengue virus RNA-dependent RNA polymerase in vitro: nucleotide, primer, and template parameters. J. Virol. 77:8831-8842.
145. Nukui, Y., S. Tajima, A. Kotaki, M. Ito, T. Takasaki, K. Koike, and I. Kurane. 2006. Novel dengue virus type 1 from travelers to Yap State, Micronesia. Emerg. Infect. Dis. 12:343-346.
146. Oishi, K., S. Inoue, M. Cinco, E. M. Dimaano, M. T. P. Alera, J. A. R. Alfon, F. Abanes, D. J. M. Cruz, R. R. Matias, H. Matsuura, F. Hasebe, S. Tanimura, A. Kumatori, K. Morita, F. F. Natividad, and T. Nagatake. 2003. Correlation between increased platelet-associated IgG and thrombocytopenia in secondary dengue virus infections. J. Med. Virol. 71:259-264.
147. Oliphant, T., M. Engle, G. E. Nybakken, C. Doane, S. Johnson, L. Huang, S. Gorlatov, E. Mehlhop, A. Marri, K. M. Chung, G. D. Ebel, L. D. Kramer, D. H. Fremont, and M. S. Diamond. 2005. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat. Med. 11:522-530.
148. Olsthoorn, R. C., and J. F. Bol. 2001. Sequence comparison and secondary structure analysis of the 3′ noncoding region of flavivirus genomes reveals multiple pseudoknots. RNA 7:1370-1377.
149. Paes, M. V., A. T. Pinhao, D. F. Barreto, S. M. Costa, M. P. Oliveira, A. C. Nogueira, C. M. Takiya, J. C. Farias-Filho, H. G. Schatzmayr, A. M. Alves, and O. M. Barth. 2005. Liver injury and viremia in mice infected with dengue-2 virus. Virology 338:236-246.
150. Perez, A. B., G. Garcia, B. Sierra, M. Alvarez, S. Vazquez, M. V. Cabrera, R. Rodriguez, D. Rosario, E. Martinez, T. Denny, and M. G. Guzman. 2004. IL-10 levels in dengue patients: some findings from the exceptional epidemiological conditions in Cuba. J. Med. Virol. 73:230-234.
151. Phoolcharoen, W., and D. R. Smith. 2004. Internalization of the dengue virus is cell cycle modulated in HepG2, but not vero cells. J. Med. Virol. 74:434-441.
152. Phuong, C. X., N. T. Nhan, R. Kneen, P. T. Thuy, C. van Thien, N. T. Nga, T. T. Thuy, T. Solomon, K. Stepniewska, and B. Wills. 2004. Clinical diagnosis and assessment of severity of confirmed dengue infections in Vietnamese children: is the World Health Organization classification system helpful? Am. J. Trop. Med. Hyg. 70:172-179.
153. Pokidysheva, E., Y. Zhang, A. J. Battisti, C. M. Bator-Kelly, P. R. Chipman, C. A. Xiao, G. G. Gregorio, W. A. Hendrickson, R. J. Kuhn, and M. G. Rossmann. 2006. Cryo-EM reconstruction of dengue virus in complex with the carbohydrate recognition domain of DC-SIGN. Cell 124:485-493.
154. Proutski, V., E. A. Gould, and E. C. Holmes. 1997. Secondary structure of the 3′ untranslated region of flaviviruses: similarities and differences. Nucleic Acids Res. 25:1194-1202.
155. Pryor, M. J., J. M. Carr, H. Hocking, A. D. Davidson, P. Li, and P. J. Wright. 2001. Replication of dengue virus type 2 in human monocyte-derived macrophages: comparisons of isolates and recombinant viruses with substitutions at amino acid 390 in the envelope glycoprotein. Am. J. Trop. Med. Hyg. 65:427-434.
156. Rico-Hesse, R., L. M. Harrison, R. A. Salas, D. Tovar, A. Nisalak, C. Ramos, J. Boshell, M. T. de Mesa, R. M. Nogueira, and A. T. da Rosa. 1997. Origins of dengue type 2 viruses associated with increased pathogenicity in the Americas. Virology 230:244-251.
157. Rigau-Perez, J. G. 2006. Severe dengue: the need for new case definitions. Lancet Infect. Dis. 6:297-302.
158. Roehrig, J. T. 2003. Antigenic structure of flavivirus proteins. Adv. Virus Res. 59:141-175.
159. Rothman, A. L. 2004. Dengue: defining protective versus pathologic immunity. J. Clin. Investig. 113:946-951.
160. Rothman, A. L. 2003. Immunology and immunopathogenesis of dengue disease, p. 397-419. In K. Maramorosch, A. J. Shatkin, F. A. Murphy, T. J. Chambers, and T. P. Monath (ed.), Flaviviruses: pathogenesis and immunity, vol. 60. Academic Press Inc., San Diego, Calif.
161. Rothman, A. L., S. Green, D. H. Libraty, and F. A. Ennis. 2005. Dengue: translating scientific progress into workable solutions. Expert Rev. Anti. Infect. Ther. 3:689-692.
162. Sabin, A. B. 1952. Research on dengue during World War II. Am. J. Trop. Med. Hyg. 1:30-50.
163. Saito, M., K. Oishi, S. Inoue, E. M. Dimaano, M. T. P. Alera, A. M. P. Robles, B. D. Estrella, A. Kumatori, K. Moji, M. T. Alonzo, C. C. Buerano, R. R. Matias, K. Morita, F. F. Natividad, and T. Nagatake. 2004. Association of increased platelet-associated immunoglobulins with thrombocytopenia and the severity of disease in secondary dengue virus infections. Clin. Exp. Immunol. 138:299-303.
164. Sakuntabhai, A., C. Turbpaiboon, I. Casademont, A. Chuansumrit, T. Lowhnoo, A. Kajaste-Rudnitski, S. M. Kalayanarooj, K. Tangnararatchakit, N. Tangthawornchaikul, S. Vasanawathana, W. Chaiyaratana, P. T. Yenchitsomanus, P. Suriyaphol, P. Avirutnan, K. Chokephaibulkit, F. Matsuda, S. Yoksan, Y. Jacob, G. M. Lathrop, P. Malasit, P. Despres, and C. Julier. 2005. A variant in the CD209 promoter is associated with severity of dengue disease. Nature Genet. 37:507-513.
165. Salonen, A., T. Ahola, and L. Kaariainen. 2005. Viral RNA replication in association with cellular membranes. Curr. Top. Microbiol. Immunol. 285:139-173.
166. Sangkawibha, N., S. Rojanasuphot, S. Ahandrik, S. Viriyapongse, S. Jatanasen, V. Salitul, B. Phanthumachinda, and S. B. Halstead. 1984. Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. Am. J. Epidemiol. 120:653-669.
167. Schrader, A. P., and E. G. Westaway. 1990. Successful competition in translation by the flavivirus Kunjin with poliovirus during co-infections in Vero cells. Arch. Virol. 114:75-89.
168. Scott, R. M., A. Nisalak, U. Cheamudon, S. Seridhoranakul, and S. Nimmannitya. 1980. Isolation of dengue viruses from peripheral blood leukocytes of patients with hemorrhagic fever. J. Infect. Dis. 141:1-6.
169. Shresta, S., J. L. Kyle, P. R. Beatty, and E. Harris. 2004. Early activation of natural killer and B cells in response to primary dengue virus infection in A/J mice. Virology 319:262-273.
170. Shresta, S., J. L. Kyle, H. M. Snider, M. Basavapatna, P. R. Beatty, and E. Harris. 2004. Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T- and B-cell-dependent immunity are less critical. J. Virol. 78:2701-2710.
171. Shresta, S., K. L. Sharar, D. M. Prigozhin, H. M. Snider, P. R. Beatty, and E. Harris. 2005. Critical roles for both STAT1-dependent and STAT1-independent pathways in the control of primary dengue virus infection in mice. J. Immunol. 175:3946-3954.
172. 171a. Shresta, S., K. L. Sharar, D. M. Prigozhin, P. R. Beatty, and E. Harris. 2006. Murine model for dengue virus-induced lethal disease with increased vascular permeability. J. Virol. 80:10208-10217.
173. Simmons, C. P., T. Dong, N. V. Chau, N. T. P. Dung, T. N. B. Chau, L. T. T. Thao, N. T. Dung, T. T. Hien, S. Rowland-Jones, and J. Farrar. 2005. Early T-cell responses to dengue virus epitopes in Vietnamese adults with secondary dengue virus infections. J. Virol. 79:5665-5675.
174. Stadler, K., S. L. Allison, J. Schalich, and F. X. Heinz. 1997. Proteolytic activation of tick-borne encephalitis virus by furin. J. Virol. 71:8475-8481.
175. Stephens, H. A., R. Klaythong, M. Sirikong, D. W. Vaughn, S. Green, S. Kalayanarooj, T. P. Endy, D. H. Libraty, A. Nisalak, B. L. Innis, A. L. Rothman, F. A. Ennis, and D. Chandanayingyong. 2002. HLA-A and -B allele associations with secondary dengue virus infections correlate with disease severity and the infecting viral serotype in ethnic Thais. Tissue Antigens 60:309-318.
176. Stephenson, J. R. 2005. Understanding dengue pathogenesis: implications for vaccine design. Bull. W. H. O. 83:308-314.
177. Sudiro, T. M., J. Zivny, H. Ishiko, S. Green, D. W. Vaughn, S. Kalayanarooj, A. Nisalak, J. E. Norman, F. A. Ennis, and A. L. Rothman. 2001. Analysis of plasma viral RNA levels during acute dengue virus infection using quantitative competitor reverse transcription-polymerase chain reaction. J. Med. Virol. 63:29-34.
178. Tadano, M., Y. Makino, T. Fukunaga, Y. Okuno, and K. Fukai. 1989. Detection of dengue 4 virus core protein in the nucleus. I. A monoclonal antibody to dengue 4 virus reacts with the antigen in the nucleus and cytoplasm. J. Gen. Virol. 70:1409-1415.
179. Tajima, S., Y. Nukui, I. A. Mikako, T. A. Tomohiko, and I. Kurane. 2006. Nineteen nucleotides in the variable region of 3′ non-translated region are ! dispensable for the replication of dengue type 1 virus in vitro. Virus Res. 116:38-44.
180. Talavera, D., A. M. Castillo, M. C. Dominguez, A. E. Gutierrez, and I. Meza. 2004. IL8 release, tight junction and cytoskeleton dynamic reorganization conducive to permeability increase are induced by dengue virus infection of microvascular endothelial monolayers. J. Gen. Virol. 85:1801-1813.
181. Tan, B. H., J. Fu, R. J. Sugrue, E. H. Yap, Y. C. Chan, and Y. H. Tan. 1996. Recombinant dengue type 1 virus NS5 protein expressed in Escherichia coli exhibits RNA-dependent RNA polymerase activity. Virology 216:317-325.
182. Tassaneetrithep, B., T. H. Burgess, A. Granelli-Piperno, C. Trumpfherer, J. Finke, W. Sun, M. A. Eller, K. Pattanapanyasat, S. Sarasombath, D. L. Birx, R. M. Steinman, S. Schlesinger, and M. A. Marovich. 2003. DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J. Exp. Med. 197:823-829.
183. Thein, S., M. M. Aung, T. N. Shwe, M. Aye, A. Zaw, K. Aye, K. M. Aye, and J. Aaskov. 1997. Risk factors in dengue shock syndrome. Am. J. Trop. Med. Hyg. 56:566-572.
184. Thepparit, C., and D. R. Smith. 2004. Serotype-specific entry of dengue virus into liver cells: identification of the 37-kilodalton/67-kilodalton high-affinity laminin receptor as a dengue virus serotype 1 receptor. J. Virol. 78:12647-12656.
185. Thomas, S. J., D. Strickman, and D. W. Vaughn. 2003. Dengue epidemiology: virus epidemiology, ecology, and emergence. Adv. Virus Res. 61:235-289.
186. Tseng, C. S., H. W. Li, H. C. Teng, W. C. Lo, and C. G. Ker. 2005. Elevated levels of plasma VEGF in patients with dengue hemorrhagic fever. FEMS Immunol. Med. Microbiol. 43:99-102.
187. Uchil, P. D., A. V. Kumar, and V. Satchidanandam. 2006. Nuclear localization of flavivirus RNA synthesis in infected cells. J. Virol. 80:5451-5464.
188. Valle, J. R. D., S. Chavez-Salinas, F. Medina, and R. M. del Angel. 2005. Heat shock protein 90 and heat shock protein 70 are components of dengue virus receptor complex in human cells. J. Virol. 79:4557-4567.
189. Vaughn, D. W., S. Green, S. Kalayanarooj, B. L. Innis, S. Nimmannitya, S. Suntayakorn, T. P. Endy, B. Raengsakulrach, A. L. Rothman, F. A. Ennis, and A. Nisalak. 2000. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J. Infect. Dis. 181:2-9.
190. Vignuzzi, M., J. K. Stone, J. J. Arnold, C. E. Cameron, and R. Andino. 2006. Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature 439:344-348.
191. Wang, S. H., W. J. Syu, K. J. Huang, H. Y. Lei, C. W. Yao, C. C. King, and S. T. Hu. 2002. Intracellular localization and determination of a nuclear localization signal of the core protein of dengue virus. J. Gen. Virol. 83:3093-3102.
192. Wang, W. K., D. Y. Chao, C. L. Kao, H. C. Wu, Y. C. Liu, C. M. Li, S. C. Lin, S. T. Ho, J. H. Huang, and C. C. King. 2003. High levels of plasma dengue viral load during defervescence in patients with dengue hemorrhagic fever: implications for pathogenesis. Virology 305:330-338.
193. Wang, W. K., S. R. Lin, C. M. Lee, C. C. King, and S. C. Chang. 2002. Dengue type 3 virus in plasma is a population of closely related genomes: quasispecies. J. Virol. 76:4662-4665.
194. Wang, W. K., T. L. Sung, C. N. Lee, T. Y. Lin, and C. C. King. 2002. Sequence diversity of the capsid gene and the nonstructural gene NS2B of dengue-3 virus in vivo. Virology 303:181-191.
195. Watts, D. M., K. R. Porter, P. Putvatana, B. Vasquez, C. Calampa, C. G. Hayes, and S. B. Halstead. 1999. Failure of secondary infection with American genotype dengue 2 to cause dengue haemorrhagic fever. Lancet 354:1431-1434.
196. Wills, B. A., E. E. Oragui, N. M. Dung, H. T. Loan, N. V. Chau, J. J. Farrar, and M. Levin. 2004. Size and charge characteristics of the protein leak in dengue shock syndrome. J. Infect. Dis. 198:810-818.
197. Wu, S. F., C. L. Liao, Y. L. Lin, C. T. Yeh, L. K. Chen, Y. F. Huang, H. Y. Chou, J. L. Huang, M. F. Shaio, and H. K. Sytwu. 2003. Evaluation of protective efficacy and immune mechanisms of using a non-structural protein NS1 in DNA vaccine against dengue 2 virus in mice. Vaccine 21:3919-3929.
198. Wu, S. J., G. Grouard-Vogel, W. Sun, J. R. Mascola, E. Brachtel, R. Putvatana, M. K. Louder, L. Filgueira, M. A. Marovich, H. K. Wong, A. Blauvelt, G. S. Murphy, M. L. Robb, B. L. Innes, D. L. Birx, C. G. Hayes, and S. S. Frankel. 2000. Human skin Langerhans cells are targets of dengue virus infection. Nat. Med. 6:816-820.
199. Yocupicio-Monroy, R. M. E., F. Medina, J. Reyes-del Valle, and R. M. del Angel. 2003. Cellular proteins from human monocytes bind to dengue 4 virus minus-strand 3′ untranslated region RNA. J. Virol. 77:3067-3076.
200. You, S., B. Falgout, L. Markoff, and R. Padmanabhan. 2001. In vitro RNA synthesis from exogenous dengue viral RNA templates requires long range interactions between 5′- and 3′-terminal regions that influence RNA structure. J. Biol. Chem. 276:15581-15591.
201. You, S., and R. Padmanabhan. 1999. A novel in vitro replication system for dengue virus. Initiation of RNA synthesis at the 3′-end of exogenous viral RNA templates requires 5′- and 3′-terminal complementary sequence motifs of the viral RNA. J. Biol. Chem. 274:33714-33722.
202. Zhang, Y., J. Corver, P. R. Chipman, W. Zhang, S. V. Pletnev, D. Sedlak, T. S. Baker, J. H. Strauss, R. J. Kuhn, and M. G. Rossmann. 2003. Structures of immature flavivirus particles. EMBO J. 22:2604-2613.
203. Zivna, I., S. Green, D. W. Vaughn, S. Kalayanarooj, H. A. Stephens, D. Chandanayingyong, A. Nisalak, F. A. Ennis, and A. L. Rothman. 2002. T cell responses to an HLA-B*07-restricted epitope on the dengue NS3 protein correlate with disease severity. J. Immunol. 163:5959-5965.